CA3246517A1 - Promédicaments d'il-12 - Google Patents

Promédicaments d'il-12

Info

Publication number
CA3246517A1
CA3246517A1 CA3246517A CA3246517A CA3246517A1 CA 3246517 A1 CA3246517 A1 CA 3246517A1 CA 3246517 A CA3246517 A CA 3246517A CA 3246517 A CA3246517 A CA 3246517A CA 3246517 A1 CA3246517 A1 CA 3246517A1
Authority
CA
Canada
Prior art keywords
compound
inducible
prodrug
tumor
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246517A
Other languages
English (en)
Inventor
William Winston
Cynthia Seidel-Dugan
Daniel Hicklin
Heather Brodkin
Jose Andres SALMERON-GARCIA
Philipp Steiner
Christopher NIRSCHL
Original Assignee
Werewolf Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werewolf Therapeutics Inc filed Critical Werewolf Therapeutics Inc
Publication of CA3246517A1 publication Critical patent/CA3246517A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"Il est décrit des méthodes et des compositions pour le traitement du cancer à l'aide d'un promédicament d'IL-12 inductible."
CA3246517A 2022-04-07 2023-04-06 Promédicaments d'il-12 Pending CA3246517A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263328708P 2022-04-07 2022-04-07
US63/328,708 2022-04-07
US202263382694P 2022-11-07 2022-11-07
US63/382,694 2022-11-07
PCT/US2023/065429 WO2023196897A1 (fr) 2022-04-07 2023-04-06 Promédicaments d'il-12

Publications (1)

Publication Number Publication Date
CA3246517A1 true CA3246517A1 (fr) 2023-10-12

Family

ID=86282116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246517A Pending CA3246517A1 (fr) 2022-04-07 2023-04-06 Promédicaments d'il-12

Country Status (6)

Country Link
EP (1) EP4504763A1 (fr)
JP (1) JP2025511754A (fr)
KR (1) KR20240169637A (fr)
AU (1) AU2023248470A1 (fr)
CA (1) CA3246517A1 (fr)
WO (1) WO2023196897A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024211877A2 (fr) * 2023-04-06 2024-10-10 Werewolf Therapeutics, Inc. Promédicaments d'il-12, procédés d'utilisation et compositions pharmaceutiques
WO2025072450A1 (fr) * 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Thérapie cellulaire adoptive améliorée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110728A2 (fr) 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
WO2019222296A1 (fr) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
CA3178657A1 (fr) * 2020-05-19 2021-11-25 William Winston Polypeptides il-12 activables et leurs procedes d'utilisation

Also Published As

Publication number Publication date
JP2025511754A (ja) 2025-04-16
EP4504763A1 (fr) 2025-02-12
WO2023196897A1 (fr) 2023-10-12
AU2023248470A1 (en) 2024-10-03
KR20240169637A (ko) 2024-12-03

Similar Documents

Publication Publication Date Title
US20240043488A1 (en) Activatable il-12 polypeptides and methods of use thereof
AU2023219887C1 (en) Activatable interleukin-2 polypeptides and methods of use thereof
US20230051423A1 (en) Activatable cytokine polypeptides and methods of use thereof
CA3246517A1 (fr) Promédicaments d'il-12
US20240216505A1 (en) Inducible cytokine prodrug and pd-1/pd-l1 combination therapy
US20240216474A1 (en) Activatable interferon polypeptides and methods of use thereof
WO2025151274A1 (fr) Promédicaments d'il-18 inductibles
WO2025072443A2 (fr) Polypeptides il-21 activables et leurs procédés d'utilisation et anticorps d'albumine sérique humaine à domaine unique
US20260125436A1 (en) Il-12 prodrugs, methods of use and pharmaceutical compositions
EP4688820A2 (fr) Promédicaments d'il-12, procédés d'utilisation et compositions pharmaceutiques
WO2026006413A1 (fr) Promédicaments à base d'il-12, procédés d'utilisation et compositions pharmaceutiques
WO2024192195A2 (fr) Promédicaments d'interféron
JP2026513879A (ja) Ｉｌ－１２プロドラッグ、使用方法、及び医薬組成物
HK40098030A (en) Activatable interleukin-2 polypeptides and methods of use thereof
HK40048553B (en) Activatable interleukin-2 polypeptides and methods of use thereof
HK40048553A (en) Activatable interleukin-2 polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240923

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241004

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241004

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241209

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260318